aspirin has been researched along with ezetimibe in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Cervera, R; Escárcega, RO; Garcia-Carrasco, M; Jara, LJ | 1 |
| Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS | 1 |
| Spence, JD | 1 |
| Barbosa, SP; Bianco, HT; Camargo, LM; Fonseca, FA; França, CN; Izar, MC; Lins, LS; Pinheiro, LF | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Kuang, H; Li, L; Lu, T; Shou, W; Yi, Q; Zhou, X | 1 |
| Barrett, HPR; Chan, DC; Ma, L; Ooi, EMM; Parhofer, KG; Waldmann, E; Watts, GF | 1 |
| Fazio, S; Weitz, JI | 1 |
| Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA | 1 |
| Tang, X; Wang, L | 1 |
1 review(s) available for aspirin and ezetimibe
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for aspirin and ezetimibe
| Article | Year |
|---|---|
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arachidonic Acid; Aspirin; Azetidines; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lower Extremity; Male; Middle Aged; Niacin; Peripheral Arterial Disease; Placebo Effect; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Stents; Time Factors; Treatment Outcome | 2011 |
Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy.
Topics: Aged; Anticholesteremic Agents; Aspirin; Azetidines; Cell-Derived Microparticles; Cholesterol, LDL; Clopidogrel; Coronary Disease; Drug Combinations; Endothelial Progenitor Cells; Ezetimibe; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Simvastatin; Ticlopidine; Triglycerides | 2014 |
11 other study(ies) available for aspirin and ezetimibe
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality.
Topics: Aspirin; Azetidines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk | 2009 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines; Carotid Stenosis; Diet, Mediterranean; Drug Therapy, Combination; Exercise Therapy; Ezetimibe; Female; Heptanoic Acids; Humans; Perindopril; Pyrroles; Risk; Stroke; Treatment Outcome; Ultrasonography; Vasodilator Agents | 2013 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report.
Topics: Adolescent; Anticholesteremic Agents; Aspirin; Coronary Disease; Ezetimibe; Female; Heart Failure; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Mutation; Myocardial Ischemia; Platelet Aggregation Inhibitors; Receptors, LDL; Xanthogranuloma, Juvenile | 2018 |
Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Aspirin; Blood Component Removal; Coronary Artery Disease; Cross-Sectional Studies; Ezetimibe; Female; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation Inhibitors; Young Adult | 2019 |
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Plaque, Atherosclerotic; Rivaroxaban; Thrombosis | 2019 |
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic Disease; Diet; Disease Models, Animal; Disease Progression; Ezetimibe; Fatty Liver; Feeding Behavior; Gallbladder Neoplasms; Gallstones; Inflammation; Male; Metaplasia; Mice, Inbred C57BL; Precancerous Conditions; Spleen | 2020 |
Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease.
Topics: Activities of Daily Living; Anticholesteremic Agents; Aspirin; Atorvastatin; C-Reactive Protein; Carotid Intima-Media Thickness; Cerebrovascular Disorders; Cholesterol, LDL; Ezetimibe; Humans; Leptin; Pyrroles; Treatment Outcome; Triglycerides | 2022 |